Form 4: Xeris Biopharma COO Kevin McCulloch's Equity Activity

Xeris Biopharma's President and COO, Kevin McCulloch, reported recent equity grants and tax-related share dispositions.

Summary

• Kevin McCulloch, President and Chief Operating Officer of Xeris Biopharma Holdings, Inc., reported several transactions involving the company's common stock and stock options.
• On January 30, 2026, McCulloch acquired 168,463 shares of common stock through a restricted stock unit (RSU) grant under the company's 2018 Stock Option and Incentive Plan. These RSUs vest in equal annual installments over three years, contingent on continued employment.
• On January 30, 2026, McCulloch also acquired 225,225 stock options with an exercise price of $7.36 per share, granted under the same 2018 Plan. These options vest in equal annual installments over three years, subject to continued service, and expire on January 30, 2036.
• On January 31, 2026, a total of 126,062 shares of common stock were disposed of (68,454, 30,289, and 27,319 shares) at a price of $7.36 per share. These dispositions represent shares withheld by the Issuer to cover income tax and withholding obligations related to the net settlement of vested restricted stock units.
• Following these transactions, McCulloch beneficially owns 1,727,827 shares of common stock directly and 25,000 shares indirectly through a spouse, while also holding 225,225 stock options directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive compensation practices that align management incentives with long-term company performance, despite the routine tax-related share dispositions.

Positives

• Kevin McCulloch received a grant of 168,463 restricted stock units, aligning his interests with long-term shareholder value.
• McCulloch was granted 225,225 stock options, providing an incentive for future performance and potential capital appreciation.

Negatives

• A total of 126,062 shares were disposed of to cover tax obligations related to vested restricted stock units, which is a common practice but reduces direct share ownership.

Future Outlook

The restricted stock units and stock options granted to Kevin McCulloch are subject to a three-year vesting schedule in equal annual installments, contingent on his continued employment or service, indicating a long-term incentive structure.

Industry Context

StockSavvy.ai notes that equity grants to executive officers like Kevin McCulloch are standard practice in the biopharmaceutical industry, serving as a key component of executive compensation packages designed to align management incentives with shareholder interests and promote long-term retention and performance. The withholding of shares for tax purposes upon vesting is also a routine event for such equity awards.

Comparison to Industry Standards

• The grant of restricted stock units and stock options to a President and COO is consistent with executive compensation practices across the biopharmaceutical sector, where equity-based incentives are prevalent.
• The three-year vesting schedule for both RSUs and stock options is a common industry standard, aiming to retain key executives and incentivize sustained performance over a multi-year horizon, similar to practices at companies like Amgen or Gilead Sciences for their senior leadership.

Stakeholder Impact

• Shareholders: The equity grants align the interests of a key executive with shareholders, potentially incentivizing long-term value creation. The tax-related dispositions are a normal part of equity compensation.
• Employees: The vesting schedule for the equity awards emphasizes the importance of continued employment for executive compensation.

Next Steps

• The restricted stock units and stock options will vest in equal annual installments over three years, subject to continued employment/service.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation, specifically equity grants and tax-related share dispositions. Such transactions are generally expected and do not typically indicate a significant change in the company's fundamental outlook or warrant a change in investment recommendation based solely on this filing. It reinforces the existing compensation structure for a key executive.

Keywords

Xeris Biopharma Holdings, XERS, Kevin McCulloch, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Equity Grant, Officer Compensation